Skip to content

Ultrasound-Guided Dry Needling with or without Platelet-Rich Plasma for Myofascial Trigger Points in Knee Osteoarthritis: A Randomized Control Trial on Muscle Mass and Clinical Outcomes

Ultrasound-Guided Dry Needling with or without Platelet-Rich Plasma for Myofascial Trigger Points in Knee Osteoarthritis: A Randomized Control Trial on Muscle Mass and Clinical Outcomes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113776
Enrollment
Unknown
Registered
2025-12-03
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Interventions

Dry Needling Group (DG):Ultrasound-guided trigger point dry needling(6 times)
The platelet-rich plasma group (PG):Ultrasound-guided trigger point dry needling(6 times) combined with PRP injection method(3 times)

Sponsors

East China Hospital Affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
50 Years to No maximum

Inclusion criteria

Inclusion criteria: The inclusion criteria for patients with knee osteoarthritis (KOA) are as follows: 1. Must meet the clinical diagnostic criteria of the American College of Rheumatology (ACR); 2. Age should be over 50 years old; 3. Confirmed by imaging examination to be at Kellgren-Lawrence (K-L) stage II to IV; 4. Have experienced knee joint pain for most of the past month (>= 15 days); 5. Baseline Numerical Pain Rating Scale (NPRS) score should be >=4 points (using a 0-10 scale); 6. And there should be at least one activated myofascial trigger point (MTrPs) in the target muscle groups such as the quadriceps, hamstring, or gastrocnemius; 7. For patients with bilateral knee arthritis, the side with a higher K-L stage will be selected as the target assessment and treatment side. If the bilateral stages are the same, the side with a higher NPRS score will be chosen.

Exclusion criteria

Exclusion criteria: 1. Within 3 months, received glucocorticoid injections into the knee joint cavity or received hyaluronic acid treatment within 6 months; 2. Previously received autologous blood products (such as platelet-rich plasma) or stem cell therapy; 3. Had systemic rheumatic diseases (such as rheumatoid arthritis, ankylosing spondylitis) or acute inflammatory diseases; 4. Had abnormal coagulation function (International Normalized Ratio INR > 1.5 or platelet count < 150×10^9/L) or was using anticoagulant/antiplatelet drugs (including aspirin, warfarin, and clopidogrel, etc.); 5. And had limited independent walking ability (defined as unable to complete the 10-meter walking test without assistive devices) or had cognitive impairment affecting the research assessment.

Design outcomes

Primary

MeasureTime frame
Numerical Pain Rating Scale(NPRS);

Secondary

MeasureTime frame
Range of Motion, ROM;Quantitative assessment of leg lean mass (dual-energy X-ray absorptiometry (DXA);Peak Torque, PT(Isokinetic muscle strength testing);

Countries

China

Contacts

Public ContactYantao Ma

East China Hospital Affiliated to Fudan University

mayantao1102@163.com+86 21 62483180

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026